Viratech Corp. (VIRA)

[Ryan8]

Cancer.im Announces Signed Agreement with the Missouri University of Science and Technology for a Clinical Breast Cancer Screening Technique

RENO, NV / ACCESSWIRE / February 1, 2016 / Cancer.im Inc. a Viratech Corp. company (OTC: VIRA) and social network for cancer patients, survivors and caretakers, announced today an agreement with Missouri University of Science and Technology (Missouri S&T) to commercialize a device that analyzes metabolic biomarkers present in urine for cancer screening applications.

The "P-scan" technology developed by Dr. Yinfa Ma and his research team at Missouri S&T is a rapid, point-of-care test for early screening of cancer that non-invasively monitors levels of pteridine biomarkers in urine. Its unique design delivers excellent sensitivity without the need for costly instrumentation. New technological modifications, such as improved interference filtering, are being used to further enhance device sensitivity and clinical accuracy.

New frontiers for health care

"The influential U.S. Preventive Services Task Force suggests waiting to start mammogram screening until age 50," says Dr. Kevin Buckman, M.D., Chief Medical Officer of Cancer.im Inc. and author of a best-selling book on breast cancer called Find and Stop Breast Cancer. "This is a real dilemma for women under 50 and for those who want a noninvasive means of breast cancer screening. Screening with molecular biomarkers may have advantages over expensive imaging technologies such as CT scans, x-rays, PET scans, mammograms, ultrasounds and other tests, since these metabolic biomarkers can better represent tumor biology. There is an urgent need to find new ways to detect breast cancer at all stages and to monitor cancer treatment following diagnosis. Pteridines present an exciting opportunity given the clinical research that is linking pteridine levels in urine to cancer."

The P-Scan device detects pteridines by measuring their fluorescence in urine, but can detect over 70 unique compounds. Some of these unknown compounds have also been shown to associate with presence of cancer. The technology has been deployed in several pilot clinical studies to evaluate the clinical performance of pteridine biomarkers in various cancers and especially breast cancer. Some of the more salient findings from these studies were that (1) Elevated pteridine levels were measured in invasive breast carcinomas; (2) Two pteridine biomarkers, xanthopterin and isoxanthopterin, provided superior performance in detecting invasive breast, and (3) Combining pteridine biomarkers with patient factors like age and previous history of breast cancer provide a new risk screening tool for clinicians that may be used to supplement or replace existing techniques like the mammogram. There are also preliminary findings that some pteridines correlate with cancer stage and may be used to detect early stage cancers that cannot be detected by conventional techniques. Further clinical studies are needed to obtain regulatory approval before the device can be used clinically.

About Cancer.im

Cancer.im Inc. is a purpose-driven corporation with a mission "To Change The Way People View and Manage Cancer." Cancer.im is a for-profit social network that supports a parallel and independently run non-profit.


On October 27, 2007, Dr. Nikolaou, on behalf of Fox Chase Medical Center, published a double blind placebo controlled study titled "Quality of Life (QOL) Supersedes the Classic Predictors of Survival in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)." This study concluded that by raising a cancer patient's quality of life via the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30 index), you could directly lower the incidence of morbidity in a cancer patient, regardless of treatment.

In 2008, Cancer.im CEO Chris Ryan with oncologist Dr. Mahesh Kanojia, Dr. Barkat Charania and Dr. Kevin Buckman adapted the above referenced study into a modular 15-part best practice navigation element and guide on teaching and assisting cancer patients in raising their quality of life.

In 2011 this adaption was published under the title "Method of Lowering a Cancer Patients' Morbidity Rate by Increasing Quality of Life of Patient, by Leveraging Cause Based Electronic Support Networks", and later renamed "The Robert Ryan Cancer Protocol" in honor of the cancer patient who inspired the study.

The Cancer.im Inc. vision is based on the Robert Ryan Cancer Protocol with a modular 15-part best practice guide on teaching and assisting cancer patients and their loved ones on the importance of Quality of Life and how to raise it when managing a diagnosis of cancer.

"Cancer.im is about empowering the cancer patients, caretakers and survivors of the network. It is an honor to serve this project, for it draws the best people who together through collaboration bring the best out of each other. The purpose of Cancer.im is to convert a cancer patient from hopeless to hopeful, while teaching their support network how to be helpful, while not being a hindrance," says Chris Ryan CEO Cancer.im Inc.

This year, nearly 1.6 million Americans will be diagnosed with cancer. Of that, 581,000 people are expected to die. Cancer accounts for 1 in every 4 deaths, second only to heart disease as the most common cause of death. The monetary cost seems irrelevant to the loss of life. Overall costs of cancer are projected to exceed $201 billion in 2013: $77 billion for direct medical costs (all health expenditures) as well as over $124 billion for the indirect mortality costs.

About Viratech Corp.

Viratech is a software company focusing on leveraging its proprietary social network platform in developing disruptor-based applications in the communication broadcasting, work flow management, crowdsourced labor and biotechnology fields.

About Missouri University of Science and Technology

Founded in 1870 as the University of Missouri School of Mines and Metallurgy, Missouri University of Science and Technology (Missouri S&T) is a research university of more than 8,900 students and part of the four-campus University of Missouri System. Located in Rolla, Missouri, Missouri S&T offers 97 degree programs in 39 areas of study and awards bachelor's, master's and Ph.D. degrees in engineering, the sciences, business and information technology, the humanities, and the liberal arts. For more information about Missouri S&T, visit www.mst.edu.

Forward-Looking Statements

Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward-looking statements in this press release include statements regarding our belief about the market applications. The following important factors, among others, have affected and, in the future could affect, the our actual results: the effect of new branding and marketing initiatives, the integration of new leadership, the introduction and acceptance of new products, the levels and particular directions of research and product development by our customers, the impact of the growing number of producers of biotechnology research and diagnostics products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of our research and product development efforts and those of companies in which we have invested or with which we have formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in our annual report and quarterly reports. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact information:

Chris Ryan
CEO Cancer.im, Inc.
www.linkedin.com/in/cancer

Fred Schiemann
CEO Viratech, Corp.
Viratech, Corp.
(775) 372–(VIRA)

SOURCE: Cancer.im, Inc.
https://finance.yahoo.com/news/cancer-im-announces-signed-agreement-123000416.html